ReoPro (abciximab), used to prevent clotting after cardiac angioplasty


Stony Brook University School of Medicine


Barry Coller MD, at Stony Brook Medicine


Platelets can form clots, which block the flow of blood, leading to a heart attack or stroke. While researching the cellular mechanism of aggregation at Stony Brook Medicine, Dr. Coller developed a monoclonal antibody that inhibits the action of a key protein receptor involved in platelet aggregation. His discovery and his subsequent collaboration with scientists at Centocor led to the creation of abciximab, a drug that effectively prevents platelets from sticking together and closing off blood vessels after angioplasty. It is distributed under the trade name ReoPro.


Research throughout 1970s and 1980s; approved by the FDA in 1997